Miliary dissemination is common in tuberculosis, but is an extremely rare form of brain metastasis. It is mainly found in patients with primary lung cancer (small cell and adenocarcinoma). Here, we presented a case of miliary metastases of lung adenocarcinoma to the brain without lesion enhancement on MRI after administration of contrast. A 38-year-old Chinese male was diagnosed with lung adenocarcinoma and received chemotherapy monthly for 6 months. At one month after completion of chemotherapy, the patient presented with headache, dizziness, and vomiting. Brain MRI revealed numerous, disseminated, tiny, rounded cystic high-signal intensity lesions on T2-weighted images, and low-signal intensity lesions on T1-weighted images, with no enhancement. In addition, a high signal on T2-weighted images and uneven enhancement with contrast in the hypophysis were noted. A right frontal lobe biopsy revealed miliary metastases originating from primary lung adenocarcinoma, which was consistent with the pathological finding of a bronchial biopsy. However, the patient and his family requested supportive treatments only, and he died 3 months after the diagnosis. In summary, this case indicates that when imaging findings are not consistent with the most likely cause of miliary brain metastasis, a biopsy is necessary to make a definitive diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797433 | PMC |
| http://dx.doi.org/10.21037/tcr-20-1898 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma: A case report.
Medicine (Baltimore)
January 2025
Department of Respiratory and Critical Care Medicine, Zhongshan City People's Hospital, Zhongshan, Guangdong Province, China.
Rationale: ROS proto-oncogene 1 (ROS1) fusion is a rare but important driver mutation in non-small cell lung cancer, which usually shows significant sensitivity to small molecule tyrosine kinase inhibitors. With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations of ROS1 have been discovered. Non-muscle myosin heavy chain 9 (MYH9) is a rare fusion partner of ROS1 gene as reported.
View Article and Find Full Text PDFAssociation of Germline Pathogenic Variants in and Other DNA Damage Response Genes With Lung Cancer Risk Among Non-Hispanic Whites and African Americans.
JCO Precis Oncol
January 2025
Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Purpose: Although lung cancer is one of the most common malignancies, the underlying genetics regarding susceptibility remain poorly understood. We characterized the spectrum of pathogenic/likely pathogenic (P/LP) germline variants within DNA damage response (DDR) genes among lung cancer cases and controls in non-Hispanic Whites (NHWs) and African Americans (AAs).
Materials And Methods: Rare, germline variants in 67 DDR genes with evidence of pathogenicity were identified using the ClinVar database.
Metagenomic and Transcriptomic Analysis Reveals Crosstalk Between Intratumor Mycobiome and Hosts in Early-Stage Nonsmoking Lung Adenocarcinoma Patients.
Thorac Cancer
January 2025
Department of Thoracic Surgery and Lung Transplantation, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China.
Background: The mycobiome in the tumor microenvironment of non-smokers with early-stage lung adenocarcinoma (ES-LUAD) has been minimally investigated.
Methods: In this study, we conducted ultra-deep metagenomic and transcriptomic sequencing on 128 samples collected from 46 nonsmoking ES-LUAD patients and 41 healthy controls (HC), aiming to characterize the tumor-resident mycobiome and its interactions with the host.
Results: The results revealed that ES-LUAD patients exhibited fungal dysbiosis characterized by reduced species diversity and significant imbalances in specific fungal abundances.
The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer.
Curr Issues Mol Biol
January 2025
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Background/objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. However, not all patients treated with these therapies would respond to treatment, and patients who respond to treatment would acquire resistance at some time point. This is why we need new biomarkers that can predict response to therapy.
View Article and Find Full Text PDFClinical difference between solitary and multiple pulmonary adenocarcinoma nodules.
Tumori
January 2025
Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Objective: we compared and analyzed the imaging features, tumor markers, pathological immunohistochemistry, and lymph node metastasis rates of solitary and multiple lung adenocarcinoma to provide a valuable reference for clinical diagnosis and treatment.
Methods: A retrospective analysis of 212 patients who underwent thoracic surgery in our hospital from 2022 to 2023, including 149 patients with a solitary lung adenocarcinoma nodule and 63 patients with multiple primary nodules. Via propensity score matching, the imaging features, tumor serological markers, pathological immunohistochemistry, and lymph node metastasis rates of the two groups were compared, and the differences in lymph node metastasis rates between solitary and multiple nodules were explored by binary logistic regression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!